Cullinan Therapeutics: Worthy Of A Small Position
2025-10-17 07:01:47 ET
Shares of autoimmune and oncology concern Cullinan Therapeutics, Inc. ( CGEM ) are down approximately 70% since May 2024, owing to a data vacuum from its off-the-shelf CD19xCD3 T cell engager CLN-978. The now autoimmune therapy should provide eagerly awaited initial data from an early-stage trial in SLE, its first since Nature Medicine articles noted the potential of CD19 outside of oncology. Trading around cash on the balance sheet with an operating runway into 2028 and an NDA expected to be filed for a non-small cell lung cancer indication in 2H25, this small cap name merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Cullinan Therapeutics: Worthy Of A Small Position
NASDAQ: NKTX
NKTX Trading
-1.76% G/L:
$2.235 Last:
289,396 Volume:
$2.30 Open:
